Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

PublicNASDAQ:SPHS
Date8/2013
Raised$65M
Post IPO Valuation

General Information

Offices

La Jolla, USA
1258 Prospect Street
La Jolla, CA, 92037
USA

People

COO
CMO
CFO
President and CEO
Board of Directors
Executive Chairman

Funding

TOTAL $35.2M
FUNDING TOTAL $35.2M
Partial Close, 4/2010
$226k
Venture Round, 9/2010
Warburg Pincus
$35M

Tags

Sophiris Bio

Sophiris Bio Inc. (NASDAQ: SPHS) is a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH or enlarged prostate), which it believes is an unsatisfied patient population with significant market potential. Sophiris is currently developing PRX302 for the treatment of BPH symptoms which is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing treatments. PRX302 is currently in Phase 3 clinical development with a blinded interim analysis expected in the second half of 2014 followed by a complete data analysis in the second half of 2015. For more information, please visit www.sophiris.com.

Recent Milestones

  • Check
    Sophiris Bio — SAN DIEGO & VANCOUVER, British Columbia--(BUSINESS WIRE)-- Sophiris Bio Inc. (NASDAQ: SPHS) (TSX: SHS) today announced that enrollment has begun and the first patients have been dosed in a Phase 3 trial of PRX302 (topsalysin) as a treatment for lower urin (10/28/13)
    Posted 1/31/14 at 12:13pm via sophiris.com
  • Check
    Sophiris Bio — SAN DIEGO AND VANCOUVER, Sept. 5, 2013 /CNW/ - Sophiris Bio Inc. (NASDAQ: SPHS, TSX: SHS) (the "Company" or "Sophiris"), a biopharmaceutical company developing a clinical stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH or e (9/5/13)
    Posted 1/31/14 at 12:12pm via sophiris.com
  • Stock
    Went public with stock symbol NASDAQ:SPHS. (8/23/13)
    Posted 8/25/13 at 7:18pm
  • Check
    Sophiris Bio — Biotech Sophiris Bio sets terms for $65 million IPO (8/2/13)
    Posted 8/11/13 at 7:14pm via nasdaq.com
  • Dollar
    Sophiris Bio received $35M in Venture Round funding. (9/29/10)
    Posted 10/31/10 at 6:29pm via protoxtherapeutics.com
  • Check
    Sophiris Bio — Warburg Pincus Agrees to Invest Up to $35 Million in Protox (9/29/10)
    Posted 10/6/10 at 7:43pm via protoxtherapeutics.com
  • Dollar
    Sophiris Bio received $226k in Partial Close funding. (4/15/10)
    Posted 12/16/13 at 1:53am via sec.gov
  • Check
    Sophiris Bio added Fahar Merchant as President and CEO.
    Posted 10/6/10 at 7:42pm
  • Check
    Sophiris Bio added Randall E Woods as President and CEO.
    Posted 8/11/13 at 7:10pm
  • Check
    Sophiris Bio added Allison Hulme as COO.
    Posted 8/11/13 at 7:10pm
  • Check
    Sophiris Bio added Richard Yocum as CMO.
    Posted 8/11/13 at 7:10pm
  • Check
    Sophiris Bio added Peter Slover as CFO.
    Posted 8/11/13 at 7:10pm
  • Check
    Sophiris Bio added William Rohn as Director.
    Posted 1/14/14 at 1:04am
  • Check
    Sophiris Bio added Lars G. Ekman as Executive Chairman.
    Posted 4/14/14 at 3:27am

Videos

Screenshots

Sophiris Bio screenshot
Above: HomePage
Uploaded: 8/12/13

Stock Price

Sources

  1. SEC (sec.gov) [edit]
  2. Warburg Pincus Agrees to Invest Up to $35 Million in Protox (protoxtherapeutics.com) [edit]
  3. Warburg Pincus Agrees to Invest Up to $35 Million in Protox (protoxtherapeutics.com) [edit]
    Biotech Sophiris Bio sets terms for $65 million IPO (nasdaq.com) [edit]
    Sophiris Bio to Present at the Stifel Healthcare Conference (investor.sophiris.com) [edit]
    Sophiris Announces First Patients Dosed in the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia (investor.sophiris.com) [edit]
Edit This Page
Last Edited 4/14/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize ยป

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy